Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Hair loss
- Personal Care Products
- Skin care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 383570
The patents are
— Prostaglandin D2 Synthase and its Products as Cause of Hair Loss and Target for Therapy;
— Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.
IPSCIO Record ID: 292798
Licensor grants an exclusive, personal, non-assignable, non-sublicensable license during the Term, after approval of a Product for Commercialization within the Territory, to import, use, have used, sell, offer for sale, resell and distribute the Product solely in the Territory.
Licensor will be the exclusive supplier of Product to Licensee,
Licensor grants, during the Term, a license in the Territory on a limited, non-exclusive, personal, non-assignable, and non-sublicensable basis to the Licensor Trademarks.
Product means a product supplied by Licensor to Licensee containing the Hair Stimulating Complex (HSC), which is a soluble formulation developed by Licensor as an injectable for hair regrowth, comprises growth factors involved in hair viability such as keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and follistatin, and is produced by neonatal cells grown under simulated embryonic conditions of hypoxia (3-5% oxygen).
The patents include Extracellular Matrix Compositions, and, Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic Conditions.
Competing Product means with respect to the Parties, any product incorporating keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and/or follistatin, other than the Products, or any other product incorporating any other hair growth factor, or a variety thereof, that directly competes against HSC or with respect to an Acquirer, any product incorporating keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and/or follistatin.
IPSCIO Record ID: 28991
U.S. Patent No. 5,527,772, 5,840,690, 6,066,618
IPSCIO Record ID: 110284
Celution 800/CRS Device An automated, electromechanical device containing multilingual, interactive software that facilitates the extraction and concentration of ADRCs, using validated algorithms programmed into the deviceâ€™s software, standardizing tissue disaggregation, centrifugation and therapeutic- specific processes.
Celution 805/CRS Consumable Set A sterile, single-use set used with the Celution Device to process tissue and extract ADRCs within a closed system.
IPSCIO Record ID: 109062
IPSCIO Record ID: 279348
— during the Research Term, a non-exclusive, worldwide, license, without the right to sublicense, under the Licensor Technology solely to perform Licensees obligations under the Research Plan; and
— an exclusive, worldwide license, including the right to sublicense, under the Licensor Technology and Licensors interest in the Joint Patent Rights, to develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products solely in the Licensee Field.
Product shall mean any final dosage form of a pharmaceutical product containing a Selected Compound for use in the Licensee Field.
Licensor Field shall mean the local administration of Excluded Compounds for
— the treatment or prevention of cardiovascular diseases and disorders in humans, including but not limited to the use of an Excluded Compound coated on a cardiovascular stent and ex vivo use of Excluded Compounds for the preparation of cells to be used in cell therapy applications; and/or any other indication in humans (excluding any indication within the Licensee Field) to which Licensor obtains rights from Third Party after the Effective Date; and/or
— the Veterinary Field. Veterinary Field shall mean Topical Application of a Licensed Compound for the treatment or prevention of any skin disease or disorder in animals, excluding humans.
Licensee Field shall mean the Topical Application of a Selected Compound or Product for the promotion of hair growth in humans (Hair Growth lndications); and/or any other indication in which Topical Application is used in humans – each, a Skin-Related Indication.
IPSCIO Record ID: 383569
Licensor grants a non-exclusive, sublicensable, transferable license under the Licensed Know-How to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Field in the Territory.
Licensor grants a non-exclusive, sublicensable, transferable license under the FTO Patents to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Territory.
Licensor will use Commercially Reasonable Efforts to transfer to Licensee all items of Licensed Know-How, including Manufacturing know-how.
For Research, Development, and Manufacturing of Licensed Products Scope & Diligence, Licensee will have sole control and responsibility for the Research, Development, Manufacture and Commercialization of all Licensed Products.
Licensor FTO Patents mean any Patents that
— are not Licensor Licensed Patents or Licensor Related Patents;
— cover manufacturing processes, including intermediates, or formulations of Compounds or Licensed Products, or uses of Compounds or Licensed Products for hair growth or the prevention of hair loss; and
— Licensor or its Affiliates Controls as of the Effective Date or during the Term.
— Licensors compound known as setipiprant ;
— all other compounds covered by the Patents listed; and
— the salts, enantiomers, racemates, polymorphs, crystalline forms, non-crystalline forms, hydrates, solvates, esters, conjugates, metabolites and prodrugs of the compounds.
— the gene encoding the chemoattractant receptor-homologous molecule expressed on Th2 cells for any species, which molecule is also known as GPR44 or DP2;
— the protein encoded by such gene; and
— all subtypes, mutants and variants thereof.
CRTH2 Antagonists means any molecule with a primary mechanism of action of antagonizing CRTH2.
Patents are titled/relate to Tetrahydropyridoindole derivatives.
IPSCIO Record ID: 320535
Licensee is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical conditions for the treatment of hair loss in male androgenetic alopecia.